Neuropeptide abnormalities in patients with early Alzheimer disease

Archives of General Psychiatry

Volumn 56, Issue 11, 1999, Pages 981-987

  Davis, Kenneth L ^a   Mohs, Richard C ^a   Marin, Deborah B ^a   Purohit, Dushyant P ^a   Perl, Daniel P ^a   Lantz, Melinda ^b   Austin, Gregory ^a   Haroutunian, Vahram ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Jewish Home and Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; NEUROPEPTIDE; SOMATOSTATIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CORTICOTROPIN-RELEASING HORMONE; ENTORHINAL CORTEX; FRONTAL LOBE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOCORTEX; NEUROPEPTIDES; PEPTIDES; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SOMATOSTATIN; TEMPORAL LOBE;

EID: 0032748277     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.56.11.981     Document Type: Article

References (35)

1. Davies P, Katzman R, Terry RD. Reduced somatostatin-like-immunoreactivity in cerebral cortex from cases of Alzheimer's disease and Alzheimer's senile dementia. Nature. 1980;288:279-280.
2. Rossor MN, Emson PC, Montjoy CQ, Roth M, Iversen LL. Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer's type. Neurosci Lett. 1980;20:373-377.
3. Beal MF, Mazurek MF, Tran VT, Chattha G, Bird ED, Martin JB. Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease. Science. 1985;229:289-291.
4. Nemeroff CB, Kizer JS, Reynolds GP, Bissette G. Neuropeptides in Alzheimer's disease: a postmortem study. Regul Pept. 1989;25:123-130.
5. Gabriel SM, Davidson M, Haroutunian V, Powchik P, Bierer LM, Purohit DP, Perl DP, Davis KL. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry. 1996;39:82-91.
6. Bissette G. Neuropeptides and Alzheimer's disease pathology. In: Beckwith BE, Saria A, Chronwall BM, Sandman CA, Strand FL, eds. Neuropeptides in Development and Aging. New York: The New York Academy of Sciences: 1997:17-29.
7. Bissette G, Cook L, Smith W, Dole KC, Crain B, Nemeroff CB. Regional neuropeptide pathology in Alzheimer's disease: corticotropin-releasing factor and somatostatin. J Alzheimer Dis. 1998;1:1-15.
8. Rossor MN, Iversen LL, Reynolds GP, Mountjoy CQ, Roth M. Neurochemical characteristics of early and late onset types of Alzheimer's disease. BMJ. 1984;288: 961-964.
9. Davies P, Terry RD. Cortical somatostatin-like immunoreactivity in cases of Alzheimer's disease and senile dementia of Alzheimer's type. Neurobiol Aging. 1981; 2:9-14.
10. Roberts GW, Crow TJ, Polak JM. Location of neuronal tangles in somatostatin neuroses in Alzheimer's disease. Nature. 1985;314:92-94.
11. Morrison JH, Rogers J, Scherr S, Benoit R, Bloom FE. Somatostatin immunoreactivity in neuritic plaques of Alzheimer's patients. Nature. 1985;314:90-92.
12. Armstrong DM, LeRoy S, Shields D, Terry RD. Somatostatin-like immunoreactivity within neuritic plaques. Brain Res. 1985;338:71-79.
13. Cross AJ, CrowTJ, Ferrier IN, Johnson JA, Bloom SR, Corsellis JA. Serotonin receptor changes in dementia of the Alzheimer type. J Neurochem. 1984;43: 1574-1581.
14. Bissetle G, Reynolds GP, Kilts CD, Widerlov E, Nemeroff CB. Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type: reduced cortical and striatal concentrations. JAMA. 1985;254:3067-3069.
15. De Souza EB, Whitehouse PJ, Price DL, Vale WW. Abnormalities in corticotropin-releasing hormone (CRH) in Alzheimer's disease and other human disorders. Ann N Y Acad Sci. 1987;512:237-247.
16. Kelley M, Kowall N. Corticotropin-releasing factor immunoreactive neurons persist throughout the brain in Alzheimer's disease. Brain Res. 1989;501:392-396.
17. De Souza EB, Battaglia G. Corticotropin-releasing hormone (CRH) receptors in brain. Adv Exp Met Biol. 1988;245:123-136.
18. De Souza EB, Whitehouse PJ, Kuhar MJ, Price DL, Vale WW. Reciprocal changes in corticotropin-releasing factor CRF-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease. Nature. 1986;319:593-595.
19. Powers RE, Walker LC, De Souza EB, Vale WW, Struble RG, Whitehouse PJ, Price DL. Immunohistochemical study of neurons containing corticotropin-releasing factor in Alzheimer's disease. Synapse. 1987;1:405-410.
20. Pomara N, Singh RR, Deptula D, LeWitt PA, Bissette G, Stanley M, Nemeroff CB. CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: its relationship to severity of dementia and monoamine metabolites. Biol Psychiatry. 1989;26: 500-504.
21. Molchan SE, Hill JL, Martinez RA, Lawlor BA, Mellow AM, Rubinow DR, Bissette G, Nemeroff CS, Sunderland T. CSF somatostatin in Alzheimer's disease and major depression: relationship to hypothalamic-pirtuitary-adrenal axis and clinical measures. Psychoneuroendocrinology. 1993;18:509-519.
22. Mouradian MM, Farah JM Jr, Mohr E, Fabbrini G, O'Donohue TL, Chase TN. Spinal fluid CRF reduction in Alzheimer's disease. Neuropeptides. 1986;8:393-400.
23. Haroutunian V, Perl DP, Purohit DP, Marin DB, Khan K, Lantz M, Davis KL, Mohs RC. Regional distribution of neuritic plaques in nondemented elderly and cases of very mild Alzheimer's disease. Arch Neurol. 1998;55:1185-1191.
24. Haroutunian V, Purohit DP, Perl DP, Marin DB, Khan K, Lantz M, Davis KL, Mohs RC. Neurofibrillary tangles in nondemented elderly and very mild Alzheimer's disease. Arch Neurol. 1999;157:169-179.
25. Mirra SS, Heyman A, McKeel D, Sumi SM, Grain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
26. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
27. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Arch Neurol. 1993;43:2412-2414.
28. Folstein M, Folstein S, McHugh P. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
29. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
30. Davis KL, Mohs RC, Marin DB, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. Cholinergic markers are not decreased in early Alzheimer's disease. JAMA. 1999;281:1401-1406.
31. Bierer LM, Haroutunian V, Gabriel S, Knott, PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the Cholinergic deficits. J Neurochem. 1995;64:749-760.
32. Fernere DM, Sagar SM. Development of somatostatin immunoreactive neurons in rat retina. Dev Brain Res. 1987;243:207-214.
33. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
34. Whitehouse PJ. Neurotransmitter receptor alterations in Alzheimer disease: a review. Alzheimer Dis Assoc Disord. 1987;1:9-18.
35. Behan DP, Khongsaly O, Owens MJ, Chung HD, Nemeroff CB, De Souza EB. Corticotropin-releasing factor (CRF), CRF-binding protein (CRF- BP), and CRF/ CRF-BP complex in Alzheimer's disease and control postmortem human brain. J Neurochem. 1997;68:2053-2060.